Sphingosine

Sphingosine

SCHEMBL195875

CCCCCCCCCCCCCC=CC(O)C(N)CO.NO

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 12/20 0.97
SPHK1 Q9NYA1 12/20 0.97
MAPT P10636 4/20 0.97
MEN1 O00255 3/20 0.97
KMT2A Q03164 3/20 0.97
CETP P11597 3/20 0.97
MAPK1 P28482 3/20 0.97
CYP2D6 P10635 3/20 0.97
ALDH1A1 P00352 3/20 0.97
GMNN O75496 2/20 0.97
LMNA P02545 2/20 0.97
GLA P06280 2/20 0.97
POLB P06746 2/20 0.97
THRB P10828 2/20 0.97
CXCR5 P32302 2/20 0.97
CCR6 P51684 2/20 0.97
BLM P54132 2/20 0.97
UBE2N P61088 2/20 0.97
TP53 P04637 2/20 0.97
CYP1A2 P05177 2/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sphingosine SCHEMBL195874 1.00 SPHK2 (0.97) SPHK2SPHK1MAPTMEN1KMT2A
Sphingosine SCHEMBL27975296 1.00 SPHK2 (0.97) SPHK2SPHK1MAPTMEN1KMT2A
Sphingosine SCHEMBL2306197 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
SCHEMBL21428474 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
Sphingosine SCHEMBL6348073 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
SCHEMBL22986939 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
Sphingosine SCHEMBL22911044 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
Sphingosine SCHEMBL21114357 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
SCHEMBL21428477 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A
SCHEMBL22986843 0.98 SPHK2 (1.00) SPHK2SPHK1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024013306-A1 COMPOSITIONS COMPRISING AMAROUCIAXANTHIN A ESTERS AND USES THEREOF GAT THERAPEUTICS, S.L. (ES) 2024-01-18 WO disclosed
EP-4306101-A1 COMPOSITIONS COMPRISING AMAROUCIAXANTHIN A ESTERS AND USES THEREOF Gat Therapeutics S.L. (ES) 2024-01-17 EP disclosed
US-20160152735-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-06-02 US disclosed
US-20160146844-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-05-26 US disclosed
EP-2164992-B1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID LPATH INC (US) 2016-05-04 EP disclosed
US-9274129-B2 Methods and reagents for detecting bioactive lipids LPATH, INC. (US) 2016-03-01 US disclosed
US-9217749-B2 Immune-derived moieties reactive against lysophosphatidic acid LPATH, INC. (US) 2015-12-22 US disclosed
US-9163091-B2 Compositions and methods for binding lysophosphatidic acid LPATH, INC. (US) 2015-10-20 US disclosed
CN-104650225-A COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE LPATH INC 2015-05-27 CN disclosed
CN-101679506-B Compositions and methods for binding sphingosine-1-phosphate LPATH INC 2015-02-25 CN disclosed
US-20020151060-A1 PEI: DNA vector formulations for in vitro and in vivo gene delivery BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-10-17 US disclosed
US-20020143062-A1 Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-10-03 US disclosed
WO-2001025255-A9 NOVEL ZINC FINGER PROTEIN BAYLOR COLLEGE MEDICINE (US) 2002-09-26 WO disclosed
WO-2002069886-A2 MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2002-09-12 WO disclosed
WO-2002060412-A2 STABILISED POLYMERIC AEROSOLS FOR PULMONARY GENE DELIVERY BOARD OF REGENTS (US) 2002-08-08 WO disclosed
WO-2002041871-A2 COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-05-30 WO disclosed
WO-2002036624-A2 METHODS, COMPOSITIONS AND THERAPEUTIC APPLICATIONS RELATING TO FORTILIN (= TRANSLATIONALLY CONTROLLED TUMOR PROTEIN, TCTP) AND MODULATORS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-05-10 WO disclosed
WO-2002032413-A2 A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-04-25 WO disclosed
WO-2002024232-A2 PEI: DNA VECTOR FORMULATIONS FOR IN VITRO AND IN VIVO GENE DELIVERY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-03-28 WO disclosed
WO-2001025255-A2 NOVEL ZINC FINGER PROTEIN BAYLOR COLLEGE OF MEDICINE (US) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152735-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID LPAR2, LPAR3, LPAR5 SPHK2 150/4885SPHK1 237/4885MAPT 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.